Page 2 - Chad Messer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Operator Welcome to the Q1 2021 Athenex, Inc. Earnings Conference Call. My name is Richard, and I'll be your operator for today's call. [Operator Instructions] I am now going to call over Mr. Steven Rubis, Senior Director, Investor Relations. Steven, you may begin. Steven Rubis -- Investor Relations Good morning, and thank you for joining our conference call. Today, we will provide an update on Athenex's business as well as a review of financial results for the first quarter of 2021. The news release detailing the results crossed the wire earlier this morning and is available on the company'...

Markets Needham analyst Chad Messer maintained a Buy rating on Esperion (ESPR – Research Report) today and set a price target of $134.00. The company’s shares closed last Tuesday at $26.88, close to its 52-week low of $23.90. According to TipRanks.com, Messer is a 4-star analyst with an average return of 9.1% and a 47.8% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceuticals, and Aeglea Biotherapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Esperion with a $47.14 a...

I-MAB (IMAB) Gets a Buy Rating from Needham In a report released today, Chad Messer from Needham assigned a Buy rating to I-MAB (IMAB – Research Report), with a price target of $75.00. The company’s shares closed last Monday at $64.01, close to its 52-week high of $65.94. According to TipRanks.com, Messer is a 4-star analyst with an average return of 8.0% and a 46.2% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceuticals, and Aeglea Biotherapeutics. Currently, the analyst consensus on I-MAB is a Strong Buy with an...

Esperion Therapeutics Inc (ESPR) Q4 2020 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Esperion Therapeutics Inc (NASDAQ: ESPR) Popular Searches Operator Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions] Please be advised that today's conference call may be recorded. I would now like to hand the conference call over to Ben Church, Investor Relations and Corporate Communications at Esperion. Please go ahead, sir. This article is a transcript of this conference call produced for...